全文获取类型
收费全文 | 4988篇 |
免费 | 224篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 42篇 |
儿科学 | 93篇 |
妇产科学 | 66篇 |
基础医学 | 697篇 |
口腔科学 | 152篇 |
临床医学 | 447篇 |
内科学 | 1173篇 |
皮肤病学 | 109篇 |
神经病学 | 569篇 |
特种医学 | 141篇 |
外科学 | 701篇 |
综合类 | 24篇 |
一般理论 | 2篇 |
预防医学 | 365篇 |
眼科学 | 33篇 |
药学 | 294篇 |
中国医学 | 3篇 |
肿瘤学 | 307篇 |
出版年
2023年 | 40篇 |
2022年 | 50篇 |
2021年 | 104篇 |
2020年 | 66篇 |
2019年 | 80篇 |
2018年 | 111篇 |
2017年 | 85篇 |
2016年 | 101篇 |
2015年 | 123篇 |
2014年 | 144篇 |
2013年 | 213篇 |
2012年 | 328篇 |
2011年 | 342篇 |
2010年 | 164篇 |
2009年 | 164篇 |
2008年 | 253篇 |
2007年 | 277篇 |
2006年 | 254篇 |
2005年 | 265篇 |
2004年 | 231篇 |
2003年 | 220篇 |
2002年 | 225篇 |
2001年 | 46篇 |
2000年 | 36篇 |
1999年 | 50篇 |
1998年 | 64篇 |
1997年 | 55篇 |
1996年 | 51篇 |
1995年 | 40篇 |
1994年 | 51篇 |
1993年 | 41篇 |
1992年 | 63篇 |
1991年 | 55篇 |
1990年 | 57篇 |
1989年 | 45篇 |
1988年 | 39篇 |
1987年 | 46篇 |
1986年 | 63篇 |
1985年 | 50篇 |
1984年 | 27篇 |
1983年 | 30篇 |
1982年 | 44篇 |
1981年 | 30篇 |
1980年 | 31篇 |
1979年 | 33篇 |
1978年 | 37篇 |
1977年 | 33篇 |
1976年 | 33篇 |
1973年 | 29篇 |
1972年 | 26篇 |
排序方式: 共有5218条查询结果,搜索用时 0 毫秒
71.
72.
This editorial refers to "Interventricular and intraventriculardyssynchrony are common in heart failure patients, regardlessof QRS duration"1 by S. Ghio et al. on page 571 Interest in ventricular dyssynchrony in heart failure patientshas been renewed recently by the introduction of cardiac resynchronisationtherapy (CRT). CRT is currently accepted as an adjunct to themedical treatment of symptomatic heart failure in patients withsevere left ventricular systolic dysfunction and ECG manifestationsof ventricular conduction delay.1 It aims to reduce the electricalconduction delay by pre-excitation of late-activated regionswith left- or biventricular pacing to restore a more synchronouscontraction pattern. Although this strategy has been provento be effective at group 相似文献
73.
74.
75.
76.
77.
78.
Elisabeth Heffermehl Lange Ragnar Nesvåg Petter Andreas Ringen Cecilie Bhandari Hartberg Unn Kristin Haukvik Ole Andreas Andreassen Ingrid Melle Ingrid Agartz 《Comprehensive psychiatry》2014
Longitudinal studies on first-episode psychosis (FEP) patients have shown a decrease of substance use disorders (SUDs) over the first years of illness, but there has been less focus on the gender aspect. The present study examines stability of alcohol and illicit substance use, with specific focus on gender, in a one year follow-up investigation of 154 FEP patients (91 men, 63 women) in Oslo, Norway, using criteria for DSM-IV substance use disorder diagnosis, the Alcohol Use Disorders Identification Test (AUDIT) and the Drug Use Disorders Identification Test (DUDIT). The results show that cannabis was the most frequently used illicit substance at both times. Significantly more men (34%) than women (13%) had a current illicit SUD at baseline. At follow-up, the rate of illicit SUDs was significantly reduced in men (18%) but not in women (11%). There were no significant gender differences in the rate of current alcohol use disorders (AUD) (men 14%; women 8%) at baseline, and no significant reduction in AUD in any of the genders at follow-up. At follow-up, total AUDIT and DUDIT scores were reduced in men only. In conclusion, the high and persistent rate of SUDs, particularly of cannabis, among men and women during the first year of treatment for psychosis should be addressed in the clinical management of the patients. Female FEP patients who are also substance users may be particularly vulnerable in this regard and warrant closer attention. 相似文献
79.
80.
Vatreptacog alfa is a genetically engineered variant of recombinant factor VIIa (rFVIIa) containing three amino acid changes. Aspartic acid, valine, and glutamine residues replace valine, glutamic acid, and methionine at positions 158, 296, and 298, respectively. These substitutions result in considerable enhancement of the intrinsic (tissue factor-independent) capability to activate factor X and the downstream hemostatic events are consequently augmented. The beneficial effects of vatreptacog alfa have been demonstrated in numerous in vitro systems attempting to mimic hemophilia and corroborated in in vivo models. Vatreptacog alfa has successfully passed through phase 1 and 2 clinical trials and the molecule is currently being explored in phase 3 clinical trial for the treatment of bleedings in hemophilia patients with inhibitors. This article describes the proposed mechanism behind the increased activity and action of vatreptacog alfa and reviews available data, which suggest that vatreptacog alfa could be a valuable addition to the existing portfolio of treatment options for hemophilia patients with inhibitors. 相似文献